2'-Fucosyllactose modulates gut microbiota and systemic metabolism in mild-to-moderate ulcerative colitis: a randomized crossover trial
2'-FL supplementation significantly increased Bifidobacterium abundance and altered fecal metabolite profiles, but showed no clear effect on conventional clinical indices of ulcerative colitis.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
2'-FL significantly modulated the gut microbiota, markedly increasing Bifidobacterium abundance (effect size 4.4%; P = 6.5×10⁻⁵). Fecal metabolite profiles shifted in ways consistent with altered microbial carbohydrate metabolism. Patient-reported disease control improved, but no treatment effect was detected on standard clinical indices.
How it was done
Randomized, double-blind, placebo-controlled crossover clinical trial in 38 patients with mild-to-moderate UC. Each arm consisted of 28 days of 2'-FL or maltodextrin placebo, separated by a washout period.
Risk of bias
The sample size is small (n=38), and the crossover design carries risk of carry-over effects, particularly for microbiota interventions. The abstract reports no mucosal or endoscopic inflammation data, limiting clinical interpretation.
What this study does NOT prove
The study does not prove that 2'-FL reduces active inflammation or alters the disease course of ulcerative colitis.
In clinical practice
Current evidence does not support recommending 2'-FL as a clinical intervention for UC. The absence of effect on conventional clinical indices warrants caution before any therapeutic application.
Limitations
The sample size is small (n=38), and the crossover design carries risk of carry-over effects, particularly for microbiota interventions. The abstract reports no mucosal or endoscopic inflammation data, limiting clinical interpretation.
Technical appendix
Version history
- 1.0 · 2026-08-25 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.